J. Murray & Associates

The FDA cleared Fujirebio's Lumipulse Plasma Ratio blood test for the early detection of amyloid plaques associated with Alzheimer's disease (AD). Lumipulse is the first in-vitro diagnostic (IVD) test used in the diagnosis of AD.

First Choice Neurology is proud to announce a groundbreaking partnership with NeuroDiscovery AI (NDAI), a national leader in artificial intelligence, data analytics, and clinical dashboarding for neurology.

Neurologists working in a hospital-integrated setting experience an average income reduction of $9,652

Naples Neurologist, Cory Lamar, MD, Joins First Choice Neurology

Dementia Specialist, Dr. Jeffrey Gelblum, Expands the Infusion Center in his Jupiter Neurology Office.

Memory Centers of America offers rapid evaluation and treatment of Alzheimer's disease.

Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.

First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr.

Dr. Jeff Gelblum will summarize this week's exciting FDA approval of Eli Lilly's new Alzheimer's medication Kisunla on Facebook LIVE, Friday, July 5th.

Visit First Choice Neurology at the AAN Annual Meeting, Booth 1643 on April 13-18 to learn about physician opportunities.